S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

ERYTECH Pharma Stock Forecast, Price & News

0.00 (0.00%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
6 shs
Average Volume
488,761 shs
Market Capitalization
$34.74 million
P/E Ratio
Dividend Yield
Price Target

ERYTECH Pharma MarketRank™ Forecast

Analyst Rating
Short Interest
0.24% of Shares Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.08) to ($1.97) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.67 out of 5 stars

Medical Sector

1197th out of 1,427 stocks

Biological Products, Except Diagnostic Industry

188th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ERYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

ERYTECH Pharma logo

About ERYTECH Pharma (NASDAQ:ERYP) Stock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

ERYP Stock News Headlines

Erytech Pharma reports Q1 results
Why Is ERYTECH Pharma (ERYP) Stock Up Today?
Erytech Pharma reports Q4 results
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Fiscal Year End


Pretax Margin


Sales & Book Value

Annual Sales
$4.95 million
Book Value
$0.87 per share


Free Float
Market Cap
$34.74 million
Not Optionable

ERYTECH Pharma Frequently Asked Questions

Should I buy or sell ERYTECH Pharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares.
View analyst ratings for ERYTECH Pharma
or view top-rated stocks.

How has ERYTECH Pharma's stock price performed in 2022?

ERYTECH Pharma's stock was trading at $2.35 at the start of the year. Since then, ERYP stock has decreased by 52.3% and is now trading at $1.12.
View the best growth stocks for 2022 here

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:
  • Mr. Gil Beyen BVBA, CEO & Director (Age 60, Pay $575.51k)
  • Mr. Eric Soyer Ph.D., Deputy GM, CFO & COO (Age 56, Pay $392.12k)
  • Dr. Jérôme Bailly Pharm.D., Deputy GM of Operations, Chief Quality Officer & Qualified Person (Age 43, Pay $241.36k)
  • Dr. Stewart Craig, Chief Technical Officer (Age 60)
  • Naomi Eichenbaum, Director Investor Relations
  • Mr. Brian Schwab, Chief Legal Officer & Gen. Counsel (Age 57)
  • Ms. Anne-Cécile Fumey, HR Director (Age 47)
  • Dr. Iman El-Hariry M.D., Ph.D., Chief Medical Officer (Age 62)
  • Dr. Philip L. Lorenzi, Consultant & Member of Scientific Board
  • Prof. Eric Raymond M.D., Ph.D., Consultant & Member of Scientific Board

What other stocks do shareholders of ERYTECH Pharma own?

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $1.12.

How much money does ERYTECH Pharma make?

ERYTECH Pharma (NASDAQ:ERYP) has a market capitalization of $34.74 million and generates $4.95 million in revenue each year.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 196 workers across the globe.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The official website for ERYTECH Pharma is www.erytech.com. The company can be reached via phone at (347) 874-4438, via email at investors@erytech.com, or via fax at 33-4-78-75-56-29.

This page (NASDAQ:ERYP) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.